NCT01981967View on ClinicalTrials.gov

Post-licensure Safety Study of IMOJEV® in Thailand

PHASE4CompletedINTERVENTIONAL
Enrollment

10,000

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

April 30, 2015

Study Completion Date

October 31, 2015

Conditions
Japanese Encephalitis
Interventions
BIOLOGICAL

IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine

0.5 mL, Subcutaneous.

BIOLOGICAL

IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine

0.5 mL, Subcutaneous.

Trial Locations (8)

10330

Bangkok

10400

Bangkok

11120

Nonthaburi

12120

Pathum Thani

26120

Nakornnayok

40002

Khon Kaen

50200

Chiang Mai

90110

Songkhla

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT01981967 - Post-licensure Safety Study of IMOJEV® in Thailand | Biotech Hunter | Biotech Hunter